Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Florax is a probiotic biological medication developed and marketed by the Brazilian pharmaceutical company Hebron. It contains live cultures of the yeast *Saccharomyces cerevisiae* (specifically strain 17). It is primarily indicated for the treatment of intestinal flora imbalances (dysbiosis) and associated symptoms such as diarrhea, including those caused by antibiotic use or gastrointestinal infections. As a probiotic, it works by restoring the natural microbial balance in the gut, competing with pathogenic microorganisms for nutrients and adhesion sites, and modulating the local immune response. It is typically administered as an oral suspension in single-dose containers (flaconetes).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Saccharomyces cerevisiae (Hebron).